Background
==========

Cohort studies addressing primary HIV infection (PHI) have been used as a tool to study the natural history of HIV and to estimate the incidence of AIDS-defining events, as well as other non-associated AIDS comorbidities. It is increasingly recognized that early host-virus interactions may influence the later course of disease \[[@B1],[@B2]\]. Therefore, follow up of patients immediately after seroconversion may help identify prognostic markers useful in the evaluation of therapeutic approaches.

To date, most studies of HIV seroconverters have been performed in Europe or North America \[[@B3]-[@B5]\]. Scarce information exists on this issue from resource-limited settings, particularly in South America, where there are different host, social and viral (i.e., subtype) characteristics that may alter the course of HIV infection \[[@B6]-[@B8]\].

In Argentina, it is estimated that there are approximately 130,000 persons living with HIV/AIDS, but only half of them are aware of their status. In 2008, more than 4000 new HIV infections were reported \[[@B9]\]. However, information regarding patients diagnosed during the early stages of infection is limited. To address this situation, a multicentre registry of patients with primary HIV infection in Argentina was started in 2008 \[[@B10],[@B11]\].

This paper describes the epidemiological, clinical, immunological and virological characteristics of the first 134 patients enrolled in our cohort with the aim of identifying potential markers associated with HIV progression.

Methods
=======

Study population
----------------

*Grupo Argentino de Seroconversión*\[[@B10],[@B11]\] is an ongoing multicentre Argentine observational cohort of patients diagnosed during primary HIV infection. This cohort was started in 2008 and includes two data sets: the first one includes patients diagnosed between 1997 and 2007, and the second prospectively follows patients diagnosed after January 2008.

Inclusion criteria for enrolment in the cohort are: age \> 16 years at first evaluation, confirmed diagnosis of primary HIV infection, and first medical and laboratory evaluation (i.e., CD4 cell count and plasma HIV RNA) within six months of the probable date of infection. Primary HIV infection is defined as: (1) detection of HIV RNA or p24 antigen with a simultaneous negative or indeterminate Western blot assay \[[@B12]\]; or (2) positive Western blot with a negative test within the previous six months Hence, it includes both acute and recent HIV-infection patients.

Structured questionnaires are used for baseline and follow-up visits. Clinical and laboratory information is updated every six months until death or loss to follow up.

In this paper, we report on patients who were diagnosed up to 31 December 2008. Analysis of disease progression was limited to the first year of infection.

Ethical considerations
----------------------

The *Grupo Argentino de Seroconversión*study protocol was approved by the Huésped Foundation Ethics Committee. All patients followed prospectively signed written informed consent before enrolment. Patients studied retrospectively signed consent at their first follow-up visit, if still alive.

Definitions
-----------

We defined PHI as \"symptomatic\" if one or more symptoms associated with acute retroviral syndrome were present \[[@B13],[@B14]\]. \"Severe symptomatic PHI\" was defined as presence of B or C events, (according to the Centers for Disease Control and Prevention 1993 classification \[[@B15]\]), any other serious non-AIDS-related events, or death at the time of HIV seroconversion.

In symptomatic patients, the date of infection was estimated as 14 days before the onset of symptoms. In asymptomatic patients, the date of infection was estimated as the midpoint between the last negative and the first positive test or one month before the date of the indeterminate or negative Western blot assay \[[@B16]-[@B18]\].

HIV progression was defined either by clinical (B or C events \[[@B15]\]), or immunological (CD4 cell count \< 350 cells/mm^3^) criteria, whichever occurred first. We chose these endpoints based on the current national and international recommendations for initiation of antiretroviral therapy \[[@B19],[@B20]\]. Analysis of disease progression was limited to those patients who did not start treatment within the first 120 days of infection.

Statistical analysis
--------------------

Quantitative variables were described using mean and standard deviation (SD) in cases where the underlying distribution was normal; median and interquartile ranges (IQR) were used for variables without normal distribution. Differences were analyzed using Student\'s t-test for independent samples or the non-parametric Wilcoxon Rank Sum test.

Categorical variables were described using proportions and percentages. Differences between proportions were analyzed with the Chi-square test, or Fisher\'s exact test. Differences were considered statistically significant for p \< 0.05, two-tailed tests. Univariate analysis was performed for the variables hypothesized as risk factors for events under study. All the variables of interest for the study were included in the multivariate analysis. Cox regression analysis was performed and the hazard risk (HR), 95% confidence interval (CI) and p value were calculated for each variable.

Progression-free survival time was measured from the estimated date of infection to the date of progression. For those patients who did not experience an event, data was censored at their last visit within their first year of infection or at treatment initiation. Time until an event was studied using Kaplan-Meier survival analysis, and the log rank test was applied for significance. Overall median time estimates, as well as median time by arm and corresponding 95% CI, are given. Kaplan-Meier plots are shown. Data analysis was performed with SPSS 15.0, 2007 (Chicago, Illinois).

Results
=======

Baseline characteristics
------------------------

As of December 2008, 134 patients with primary HIV infection were enrolled in the cohort; 99 retrospectively and 35 prospectively. Baseline characteristics are summarized in Table [1](#T1){ref-type="table"}. Most patients were male (n = 109) with a median age of 32 years (IQR 25-39). More than half of the patients (53%) defined themselves as men who have sex with men (MSM), while 50 (37%) reported heterosexual exposure. Only one patient reported intravenous drug use as the probable route of infection.

###### 

Baseline characteristics of *Grupo Argentino de Seroconversión*cohort (N = 134)

  ---------------------------------------------------------------------------------------------------------
  Characteristic                            All (N = 134)   Symptomatic PHI   p              
  ----------------------------------------- --------------- ----------------- -------------- --------------
  Age at HIV diagnosis, mean years (SD)     33.4 (10.7)     33.8 (10.37)      32.2 (11.64)   0.44

                                                                                             

  Male sex, n (%)                           109 (81.3)      79 (79.8)         30 (85.8)      0.61

                                                                                             

  High school education or more, n (%)      79 (75.2)       59 (72.8)         20 (83.4)      0.3

                                                                                             

  Born in Buenos Aires, n (%)               74 (67.9)       56 (67.5)         18 (69.2)      0.61

                                                                                             

  Employed, n (%)                           82 (70.7)       62 (70.5)         20 (71.4)      0.89

                                                                                             

  Reason for HIV test, n (%)                                                                 

                                                                                             

  Physician\'s suspicion                    61 (48.4)       56 (59.6)         5 (15.6)       **\< 0.001**

                                                                                             

  Patient request                           42 (33.3)       27 (28.7)         15 (46.9)      

                                                                                             

  Routine                                   23 (18.3)       11 (11.7)         12 (37.5)      

                                                                                             

  Risk factor for HIV transmission, n (%)                                                    

                                                                                             

  MSM                                       71 (53)         51 (51.5)         20 (57.1)      0.788

                                                                                             

  Heterosexual                              50 (37.3)       38 (38.4)         12 (34.3)      

                                                                                             

  IDU                                       1 (0.7)         1 (1)             0 (0)          

                                                                                             

  Missing                                   12 (9)          9 (9)             3 (8.6)        

                                                                                             

  HIV RNA, median log~10~copies/mL\         4.87\           5.12\             4.36\          **\< 0.001**
  (IQR)                                     (4.11-5.51)     (4.49-5.69)       (3.43-4.95)    

                                                                                             

  CD4 cell count, median cells/mm^3^\       479\            466\              533\           **0.019**
  (IQR)                                     (341-682)       (327-609)         (425-814)      

                                                                                             

  HAART initiation, n (%)                   42 (31.3)       39 (39.4)         3 (8.6)        **0.003**
  ---------------------------------------------------------------------------------------------------------

MSM-men who have sex with men; IDU-injection drug user; HAART-highly active antiretroviral therapy

Most of the patients (n = 74) were from Buenos Aires city and its surroundings suburbs, areas that concentrate 44% of people living with HIV/AIDS in Argentina \[[@B9]\]. Seventy-five percent of patients completed at least high school and 29% were unemployed. HIV testing was requested based on a physician\'s clinical suspicion in 48% of cases and because of patient\'s request in 33% of cases. In 18% of cases, HIV seroconversion was diagnosed in patients undergoing periodic HIV testing. Of note, three patients were diagnosed during pregnancy. The source of transmission could be identified in 52 cases. In 28 (54%) of these, a stable HIV-positive partner was identified.

At first evaluation, the Western blot test was negative in 12 patients (9%) and indeterminate in 53 (40%). In 26 of these cases, a virologic test (p24 antigen or HIV viral load) defined the diagnosis. All cases with initial negative or indeterminate Western blot had HIV infection confirmed by subsequent seroconversion. The remaining 69 (51%) patients with a reactive Western blot had a negative test within the previous six months.

The first laboratory evaluation (HIV viral load and CD4 cell count) was done at a median of 66 days (IQR 48-112) after the probable date of exposure to HIV. Median HIV-1 RNA VL was 4.87 log~10~copies/mL (IQR 4.11-5.51) and the median absolute and percentage CD4 cell count were 479 cells/mm^3^(IQR 341-682) and 23% (IQR 17-28), respectively. Baseline CD4 cell counts were \< 350 and \< 200 cells/mm^3^in 27% and 6.25% of patients, respectively. A total of 42 patients (31%) started HAART during the acute phase, with a median time of 84 days (IQR 53-110), from the probable date of infection: 39 due to symptomatic infection, and in three asymptomatic cases, due to pregnancy. Since indication of HAART during PHI is considered optional in Argentina \[[@B20]\], the decision on whether to start treatment or not depended on the physician in charge.

Morbidity and mortality associated with acute HIV infection
-----------------------------------------------------------

Ninety-nine patients (74%) presented with acute retroviral syndrome, lasting a median of 16 days (IQR 8-29). Twenty-six of them developed severe symptoms: seven opportunistic infections (three *Pneumocystis jiroveci*pneumonia, one histoplasmosis, one cryptococcal meningitis, one esophageal candidiasis and one pulmonary TB); nine B events (thrush, herpes zoster) and 10 non-AIDS defining severe events. The latter included aseptic meningitis, rhabdomyolysis with multi-organ failure, acute hepatitis, Bell\'s paralysis and guttate psoriasis.

Thirty-five patients (26.2%) required hospital admission. One patient developed chronic hydrocephaly and cognitive impairment secondary to cryptococcal meningitis and another suffered fatal disseminated histoplasmosis.

Factors associated with severe symptomatic seroconversion were CD4 cell counts lower than 350 cell/mm^3^(p = 0.001) and viral loads higher than 100,000 copies/mL (p = 0.001). HIV testing was requested more frequently by physicians based on clinical suspicion rather than patients\' initiative (OR 5.06; 95% CI 1.83-14.04). We found no association between age, gender, birth place, risk factor or year of diagnosis with regard to severity of symptoms (Table [2](#T2){ref-type="table"}).

###### 

Factors associated with severe symptomatic PHI (univariate analysis) (n = 26)

  Risk factor                              OR (95%CI)          p
  ---------------------------------------- ------------------- --------------
  Age at seroconversion \> 30 years        1.36 (0.63-2.92)    0.495
                                                               
  Male sex                                 2.52 (0.63-10.04)   0.246
                                                               
  Mode of HIV transmission (MSM)           1.14 (0.51-2.55)    0.58
                                                               
  Diagnosis based on physician suspicion   5.06 (1.83-14.04)   **\< 0.001**
                                                               
  CD4 cell count \< 350 cells/mm^3^        3.72 (1.83-7.58)    **0.001**
                                                               
  HIV RNA \> 100,000 copies/mL             3.72 (1.58-8.77)    **0.001**
                                                               
  Year of diagnosis ≥ 2005                 0.79 (0.37-1.70)    0.619

MSM-men who have sex with men

12-month morbidity and mortality
--------------------------------

### Untreated patients

Among the ninety-two patients who did not start HAART during acute HIV infection, 24 (26%, 95% CI: 17.5-36.3) patients presented with disease progression within the first year of infection: 12 had clinical progression (five AIDS-defining events and seven B events) and 12 exhibited immunological progression (CD4 cell count \< 350 cells/mm^3^). The median time between the probable date of infection and the event presentation was 182 days (IQR 67-233). One patient who developed a non-Hodgkin lymphoma within six months of HIV infection died shortly after diagnosis.

Among untreated patients, progression was observed in 20 out of 60 symptomatic patients and in 4 out of 32 asymptomatic patients. Using Kaplan-Meier curves, estimated rates of progression at 12 months of follow up were 34% (95% CI 22.5-46.3%) among symptomatic untreated patients versus 13% (95% CI 1.1- 24.7%) in the asymptomatic group. The difference between the two curves was statistically significant (p = 0.04) (Figure [1](#F1){ref-type="fig"}). The hazard ratio of disease progression for untreated persons with symptomatic primary HIV infection compared with asymptomatic seroconverters was 8.44 (95% CI 0.97-73.42).

![**Time to progression of HIV disease among untreated patients from the *Grupo Argentino de Seroconversión***. Progression-free survival from onset of HIV infection among untreated patients with or without symptomatic primary HIV infection.](1758-2652-14-40-1){#F1}

Factors associated with faster progression among untreated patients during the first year of infection were symptomatic primary HIV infection (p = 0.046), higher viral load at baseline and at six months from seroconversion (p = 0.04 and 0.008, respectively), as well as lower baseline CD4 cell count (p = 0.002). No association was found with age at seroconversion, gender, mode of HIV acquisition and year of infection. In the multivariate analysis (Table [3](#T3){ref-type="table"}), only symptomatic primary HIV infection (p = 0.049) and baseline viral load higher than 5 log~10~copies/mL (p = 0.022) remained as independent predictors of faster progression; relative risks 8.44 (95% CI 0.97-73.42) and 9.44 (95% CI 1.38-64.68), respectively. Baseline CD4 and viral load at six months were no longer associated with increased risk of progression in the multivariate model.

###### 

Predictors of disease progression in untreated patients (unadjusted and adjusted analysis) (n = 92)

  Risk factor                                Unadjusted HR (95%CI)   p           Adjusted HR (95%CI)   p
  ------------------------------------------ ----------------------- ----------- --------------------- -----------
  Symptomatic PHI                            1.41 (1.08- 1.83)       **0.046**   8.44 (0.97-73.42)     **0.049**
                                                                                                       
  Age at seroconversion \> 30 years          1.40 (0.93- 2.10)       0.159       4.42 (0.91-21.47)     0.065
                                                                                                       
  Mode of HIV transmission (MSM)             1.38 (1.02-1.86)        0.081       0.99 (0.11-8.64)      0.995
                                                                                                       
  Baseline CD4 cell count ≤ 350 cell/mm^3^   3.81 (1.64-8.86)        **0.002**   3.14 (0.47-20.78)     0.236
                                                                                                       
  Baseline HIV RNA ≥ 100,000 copies/mL       1.91 (1.08-3.39)        **0.043**   9.44 (1.38-64.68)     **0.022**
                                                                                                       
  HIV RNA at 6 months ≥ 100,000 copies/mL    9.88 (1.30-75.20)       **0.008**   2.24 (0.19-26.14)     0.520
                                                                                                       
  Male sex                                   1.07 (0.89-1.29)        0.752       3.33 (0.16-67.54)     0.433
                                                                                                       
  Year of diagnosis ≥ 2005                   0.81 (0.61-1.09)        0.146       2.10 (0.20-21.99)     0.537

PHI-primary HIV infection; MSM-men who have sex with men

### Evolution among treated patients

Among those patients who started HAART within the first 120 days of HIV infection, only three (7%) presented with HIV progression (one C event, one B event and one CD4 cell count decrease to \< 350 cells/mm^3^despite HAART initiation) within the first year of infection. The difference to the 26% progression rate seen in the untreated group was statistically significant (p = 0.01). Of note, the C event was pulmonary TB, which is endemic in Argentina.

Discussion
==========

This study is the first report from the only multicentre cohort of HIV seroconverters in Argentina and one of the few descriptions of HIV-1 progression from seroconversion in Latin America.

In our cohort, the proportion of patients with symptomatic disease was similar to previous series \[[@B13],[@B17],[@B21],[@B22]\]. Of note, one-quarter presented with serious clinical manifestations associated with seroconversion. Even though these have been previously reported \[[@B23]-[@B26]\], our results regarding the relatively high frequency of serious clinical manifestations during primary HIV infection are rather unusual. In our study, severe PHI was strongly associated with higher baseline viral load and low CD4 cell count, which is also consistent with other reports \[[@B27]-[@B29]\]. Likewise, during acute HIV infection, opportunistic infections are usually associated with low CD4 cell count. In our study, however, four out of five AIDS-defining events registered after the first 60 days of HIV infection were associated with CD4 counts greater than 200 cells/mm^3^(Table [4](#T4){ref-type="table"}), thereby highlighting the need to consider opportunistic infection even in patients with moderate immune deficiency.

###### 

AIDS-defining events during the first year of infection

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Subject   Event                     Time from HIV infection to event (days)   **CD4 cell count**(**cells/mm^3^)**   Outcome
  --------- ------------------------- ----------------------------------------- ------------------------------------- --------------------------------------------------------
  1         PCP                       15                                        27                                    Resolved, HAART initiated

                                                                                                                      

  2         PCP                       15                                        13                                    Resolved, HAART initiated

                                                                                                                      

  3         Cryptococcal meningitis   60                                        227                                   Cognitive impairment secondary to chronic hydrocephaly

                                                                                                                      

  4         Disseminated\             32                                        42                                    Death
            histoplasmosis                                                                                            

                                                                                                                      

  5         Esophageal candidiasis    9                                         134                                   Resolved, HAART initiated

                                                                                                                      

  6         Pulmonary TB              28                                        419                                   Resolved with TB treatment

                                                                                                                      

  7         PCP                       25                                        199                                   Resolved, HAART initiated

                                                                                                                      

  8         Cytomegalovirus disease   92                                        278                                   Resolved, HAART initiated

                                                                                                                      

  9         Non-Hodgkin lymphoma      210                                       28                                    Death

                                                                                                                      

  10        Pulmonary TB              203                                       553                                   Resolved with TB treatment

                                                                                                                      

  11        Cryptosporidiosis         120                                       570                                   Resolved

                                                                                                                      

  12        Kaposi\'s sarcoma         230                                       828                                   Resolved, HAART and quimiotherapy initiated
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

PCP-*Pneumocystis jiroveci*pneumonia; TB-tuberculosis

Most of our patients were young males, with MSM being slightly overrepresented compared with the current proportion in the local HIV epidemic, where heterosexual intercourse is the most common mode of HIV transmission \[[@B9]\]. Greater awareness regarding acute retroviral syndrome (ARS), the higher frequency of testing among this population, and the inclusion in the cohort of a voluntary counselling and testing centre, where most of the attendants are MSM, could have influenced our results. In addition, medical prejudice could have resulted in higher recognition of ARS in MSM patients than in the heterosexual population. This could also partly explain the lower proportion of women in our cohort compared with Argentina\'s overall HIV population \[[@B9]\] (19% vs. 39%), limiting the generalization of our findings.

One-quarter of the patients who did not start HAART during the acute phase met clinical or immunological criteria (\< 350 CD4 cells/mm^3^) \[[@B19],[@B20]\] to initiate HAART during the first year of HIV infection. This observation is particularly relevant as one-third of the patients were already excluded in the progression analysis due to HAART initiation during the acute HIV phase, which resulted in the exclusion of a considerable proportion of symptomatic patients with risk of progression. The progression rate described here is much higher than in earlier epidemiological reports \[[@B30]\], which estimated a window of several years before the need for HAART initiation. However, a recent study by CASCADE cohort investigators \[[@B31]\] found that nearly 30% of their patients had ≤ 500 CD4 cells/mm^3^12 months after infection.

Symptomatic PHI and baseline HIV RNA \> 100,000 copies/mL were identified in our study as predictors of disease progression in the multivariate model. These findings are consistent with prior studies \[[@B2],[@B3],[@B28],[@B29],[@B32]\]. While high viral loads during acute HIV infection are typically described \[[@B33],[@B34]\], low plasma levels of HIV RNA have also been reported \[[@B7],[@B35]\]. Comparisons across cohorts are difficult. However, an interesting finding of our study was that compared with European and North American cohorts of seroconvertors \[[@B3],[@B4]\], baseline HIV RNA was higher and closer to levels seen in reports from African \[[@B8]\] and Asian \[[@B2]\] countries.

Although some differences in early laboratory values may be accounted for by differences in the quantitative methods used or the length of seroconversion intervals, first viral load measurement in our cohort was done at a median of 66 days from the probable date of infection, similar to most of the published studies \[[@B2]-[@B4],[@B8]\]. There is growing evidence that initial viral load measurements, as well as the subsequent course of HIV infection, may be affected by viral \[[@B36]-[@B39]\] and host factors, including age, gender \[[@B40],[@B41]\], race \[[@B42]\] and genetics \[[@B43],[@B44]\].

In our cohort, the relative risk of disease progression in patients with baseline viral loads of \> 100,000 copies/mL was almost 10-fold. Taking into account that more than 40% (59/134) of the patients enrolled in our cohort presented with initial viral load levels above this threshold, the impact of this finding as a prognostic factor on the subsequent course of infection deserves to be highlighted. Viral load at six months, however, did not correlate with progression; likewise, neither did CD4 cell count at baseline or six months, which underscores the need to identify other markers of progression at this early stage of infection.

Recent evidence suggesting an increase in HIV virulence over time \[[@B31],[@B45]-[@B47]\] could not be corroborated, as patients who seroconverted before or after 2005 presented with similar median CD4 cell count (481 cells/mm^3^vs. 477 cells/mm^3^; p = NS) and disease progression (p = 0.537). However, the relatively small size of our cohort prevents us from formulating definite conclusions on this topic.

Our study has several limitations. First, it is possible that current clinical practice in Argentina limited identification to only the most symptomatic patients, which could have contributed to the faster progression seen in our cohort. In our country, universal access to HIV testing is guaranteed by law, but there are structural, social and economic barriers to access. It is estimated that at least 50% of infected people still remain unidentified \[[@B9]\]. Except for antenatal care, testing is usually conducted in specialized centres. HIV testing in emergency rooms, for example, is usually not accessible. These practices could have resulted in HIV testing being requested only in those patients with a more severe clinical picture, or with evident epidemiological risk. Although we cannot rule out this possibility, 26% of patients in our cohort were asymptomatic.

Second, many of the symptomatic patients started HAART during PHI, and were therefore excluded from the analysis. This could have lead to a more conservative estimate of the risk of disease progression. Third, inclusion of patients with different seroconversion intervals (i.e., acute and recent HIV infection) could have influenced our results. However, we compared rates of progression between pre- and post-seroconversion patients and found no meaningful differences (32% vs. 22%; p = 0.39).

In addition, due to the retrospective-prospective design of this study and the availability of stored blood samples only for a subset of patients enrolled after 2008, we could not study biological factors affecting immune dysregulation, such as viral tropism \[[@B39],[@B48]\], specific HLA haplotypes \[[@B48],[@B49]\] and regulatory T cells \[[@B50],[@B51]\]. Our research group is currently conducting other studies to understand the role of these biologic factors in the course of HIV infection.

Finally, information regarding viral subtype and genotypic analysis were not available for all patients and therefore it is not presented here. It is possible that HIV subtype could influence viral load set point and subsequent course of HIV infection \[[@B36]-[@B38]\]. We are currently studying the potential influence of the two most prevalent subtypes of HIV-1, B and BF \[[@B52]-[@B56]\], on disease progression in our country.

Conclusions
===========

In conclusion, the data presented here have direct implications for providing HIV care in Argentina. First, acute retroviral syndrome was associated with faster progression, significant morbidity and, in some cases, with HIV-associated mortality. Therefore, awareness needs to be raised among physicians to include HIV in their differential diagnosis of febrile illness, especially in high-risk groups, such as serodiscordant couples, sexual workers, injection drug users and MSM. Likewise, HIV should be considered in any sexually active person who presents in the emergency room with flu-like syndrome as nearly 1% of them may have acute HIV infection \[[@B57],[@B58]\].

Furthermore, this data should be taken into consideration when making decisions on treatment initiation. Patients with acute retroviral syndrome or high baseline viral load should be considered for treatment initiation, as our data suggest that approximately one-third of them will require treatment in the following year; new evidence also suggests benefits of earlier treatment initiation \[[@B59],[@B60]\].

Combined with other ongoing research in this field, the data presented here could provide valuable information on the complex interplay between virus and host factors in HIV pathogenesis that could aid in the development of better algorithms, new therapeutic approaches and the design of preventive interventions.
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